C5 IMPACT OF ATRIAL HIGH RATE EPISODES ON PROGNOSIS IN PACEMAKER PATIENTS: A SINGLE CENTRE EXPERIENCE

Background

The occurrence of high atrial rate episodes (AHRE) is growing in importance due to the increasing number of patients with implantable cardiac electronic devices (CIED). As a result, clinicians need to balance the benefits of a pharmacological therapy against the risks involved. To date, there are no clear evidence on the long–term effects of AHRE, nor are there any specific recommendations to help physicians make the most appropriate treatment choice.

Methods

We enrolled 732 patients with CIED followed in the Arrhythmology department of San Filippo Neri Hospital, in Rome and with remote home monitoring. Only patients with single–chamber, dual–chamber and biventricular pacemakers (CRT–P) were included. All patients had post–implantation follow–up at 6 months and one year. The minimum follow–up duration considered was 24 months. Patients with permanent pre–implant atrial fibrillation were excluded.

Results

Among the enrolled cohort, AHRE were found in 170 (23.2%) patients. The occurrence of AHRE was significantly related to older age (p = 0.001 HR 1.02 CI 95%), lower ejection fraction (p = 0.027 HR 0.98 CI 95%) and severe mitral valvulopathy (p = 0.003 HR 1.7 CI 95%). The presence of AHRE increased the risk of cryptogenic stroke only for episodes over 24 hours (p = 0.02 HR 1.6 CI 95%) and increased mortality (HR 1.32 CI 95%), although not significantly (p = 0.132).

Conclusion

AHRE are associated with adverse events and may increase mortality in patients with CIED. Their monitoring and detection is necessary for an appropriate management of treatments. Randomised studies are needed to clarify the criteria for thromboembolic prevention in the context of AHRE.

Single shock endocavitary low energy intracardiac cardioversion of chronic atrial fibrillation

BACKGROUND

Discomfort related to low-energy internal cardioversion (LEIC) represents a real problem in patients (pts) with atrial fibrillation (AF). The aim of our study was to verify if a single shock could restore sinus rhythm (SR) with a lower discomfort for the pt.

METHODS

Thirty pts with chronic AF were randomized to receive a single 350 V shock (15 pts) or multiple shocks of increasing energy (15 pts). Three leads were positioned, respectively, in the coronary sinus and in the lateral right wall for shock delivery, and in the right ventricular apex for R wave synchronization. Truncated, biphasic shocks were used. In the first group a single 350 V shock was directly delivered and a second 400 V shock was given only if SR has not been restored. In the second group, beginning at 50 volts the voltage was increased in steps of 50 volts until SR restoration. No patient was sedated. After each shock the pts were asked to rate their discomfort on a scale of 1 to 5 (1 = not perceived, 5 = severe discomfort).

RESULTS

SR was restored in all the subjects. In group 1 SR was obtained in 12/15 (80%) pts with the first 350 V (8.1 +/- 0.8 joules) shock, while the remaining 3 patients required the second 400 V (10.2 +/- 0.3 joules) shock. In group 2 the mean atrial defibrillation threshold was 346.7 +/- 1029.7 volts (8.0 +/- 101.5 joules). Then discomfort score was 2.5 +/- 0.6 in group 1 and 3.3 +/- 10.6 in group 2 (p < 0.01).

CONCLUSIONS

A single shock of 350 V restores SR in the majority of pts with chronic AF; by use this new approach, LEIC is tolerated better than the multiple shocks step-up protocol.

Spatial extension of local pacing capture in the lateral free wall of the right atrium during clinical chronic atrial fibrillation

OBJECTIVES

The aims of our study were to define the spatial extension of local atrial pacing capture (LAPC) in the right lateral atrial wall and to verify the effects of antiarrhythmic drugs on capture extension.

BACKGROUND

Recently, LAPC during spontaneous chronic atrial fibrillation (AF) has been demonstrated directly in humans, but no systematic attempt has been made to evaluate its spatial extension.

METHODS

The study was conducted in 14 consecutive patients with chronic AF, nine of whom were taking antiarrhythmic drugs. A Franz catheter for pacing and monophasic action potential recording was positioned in the lateral right atrial wall. An octopolar recording lead was positioned about 10 mm apart. The presence of atrial capture and its extension (number of captured bipolar pairs) were evaluated during decremental pacing.

RESULTS

Forty-eight atrial capture attempts were made. LAPC was achieved in all the performed attempts. The AF types immediately before capture were type 1 in 35 (73%) and type 2 in 13 (27%) episodes. In 32 episodes, the capture was lost within 15 seconds and in the remaining 16 pacing was stopped after 15 seconds of stable capture. In 26 episodes, capture extended radially up to 4 cm from the pacing site, in 18 up to 3 cm, in 3 up 1 cm and in 1 up 1 cm. The mean extension in patients being treated with antiarrhythmic drugs was significantly greater than what was seen in untreated patients (3.8 +/- 0.4 vs 2.9 +/- 0.7 cm, p < 0.00001). Capture loss was less frequently observed when all four of the bipolar recording sites had been captured (13/25, 52% vs 19/23, 82%, respectively, p = 0.05).

CONCLUSIONS

LAPC in the lateral right atrial wall extends over a radius of 30-40 mm in the majority of capture episodes and is greater in patients treated with antiarrhythmic drugs. Our results suggest that, at least theoretically, simultaneous multisite pacing could be used to terminate AF. Moreover, a reduction in the atrial defibrillation threshold could be expected performing low-energy internal cardioversion during LPC.

[The efficacy of high- and low-energy intracavitary cardioversion in chronic atrial fibrillation refractory to transthoracic cardioversion]

BACKGROUND

The purpose of our study was to evaluate the efficacy and safety of intracavitary cardioversion (IC) with either high (HEIC) or low (LEIC) energy in patients with chronic atrial fibrillation (AF) refractory to external cardioversion.

METHODS

Forty patients underwent IC with either high (30 pts) or low energy (10 pts); HEIC was performed by delivering one or more shocks between one electrode of the lead positioned in the right atrium and a back plate. The following energy values were used in sequence: 100, 200, 300 joules. In LEIC shocks were delivered between two custom-made decapolar leads (one in the coronary sinus and another one in the right lateral atrial wall) beginning from 50 Volts and increasing the voltage by steps of 50 Volts. Another catheter in the right ventricular apex was used for ventricular synchronization.

RESULTS

Sinus rhythm was restored in 24/30 (80%) patients undergoing HEIC and in 10/10 (100%) patients undergoing LEIC. No serious or permanent complications occurred.

CONCLUSIONS

HEIC and LEIC are effective in patients with AF refractory to external cardioversion. Both the procedures seem to be safe.

Head-up tilt testing potentiated with low-dose sublingual isosorbide dinitrate: a simplified time-saving approach for the evaluation of unexplained syncope

BACKGROUND

Head-up tilt testing is widely used in the clinical assessment of patients with unexplained syncope. However, the lack of a standard methodology and the conflicting results concerning sensitivity and specificity of the procedure have prompted further studies to define a more cost-effective approach for tilt testing.

OBJECTIVES

Our clinical investigation was undertaken to assess the diagnostic value in unexplained syncope of a simple and time-saving protocol for head-up tilt testing, including low-dose sublingual isosorbide dinitrate administration.

PATIENTS AND METHODS

A group of 73 consecutive patients (43 women and 30 men, mean age 39.6+/-21.8 years) with unexplained syncope despite conventional clinical cardiovascular and neurologic assessment and 10 asymptomatic control subjects underwent head-up tilt testing with isosorbide dinitrate challenge. Participants were tilted at 60 degrees for 30 minutes without medication; if no symptoms occurred, 1.25 mg of isosorbide dinitrate was administered sublingually and tilting was continued for an additional 15 minutes.

RESULTS

During the drug-free phase of the test 14 (19.2%) patients had syncope. After isosorbide dinitrate administration syncope occurred in another 28 patients (38.3%); minor symptoms in association with hypotension developed in 10 (13.7%) patients. The test result was negative in all control subjects. The positive rate and specificity of head-up tilt testing with isosorbide dinitrate provocation were 57.5% and 100%, respectively.

CONCLUSIONS

This new practical diagnostic procedure was found to be fairly sensitive and clearly specific in inducing a vasovagal reflex in patients with syncope of uncertain origin. Consequently, such approach could give a significant contribution in the diagnostic workup of these patients.

[Acute effects of ventricular and bicameral stimulation on plasma levels of natriuretic hormone]

Atrial natriuretic factor (ANF) is a peptide produced by the atrium in response to increases in atrial pressure. It is a potent vasodilator and recent studies suggest that ANF may modulate vasomotor changes in patients (pts) with pacemaker (PM) syndrome. To evaluate the incidence of pacing mode on peptide secretion, plasma concentrations of ANF were determined in 32 pts (18 men and 14 women, mean age 71 +/- 4 years) with a DDD PM implant. Blood samples were collected one hour after a randomly assigned PM programming either in VVI or DDD mode at 70 ppm. Mean plasma ANF levels were 84.12 +/- 51 pg/ml in DDD mode and 156.0 +/- 15 pg/ml in VVI mode (p < 0.05). In 12 pts presenting ventriculoatrial retroconduction, the ANF levels were 77.16 +/- 50 pg/ml during DDD stimulation and 219.0 +/- 16 pg/ml during VVI stimulation (p < 0.05). ANF level was 88.50 +/- 46 pg/ml in DDD mode and 114.25 +/- 65 pg/ml in VVI mode in the 20 pts without AV retroconduction (p < 0.05). During DDD mode, 18 patients showed a DVI stimulation whereas 14 showed a VDD stimulation: the mean ANF level was 67.40 +/- 15 pg/ml during DVI and 100.40 +/- 28 pg/ml during VDD stimulation; the difference between these data was not significant. The increase in ANF levels during VVI pacing confirms the lower haemodynamic performance of this stimulation mode. The increase of ANF levels during VVI stimulation, which was in the subgroup without AV retroconduction, confirms the benefits of DDD stimulation also in this group of patients as well. Atrial pacing at physiological rates does not trigger the release of ANF.

[Electrophysiologic characteristics of the atrium during chronic atrial fibrillation in man]

AIM OF THE STUDY

To evaluate the electrophysiologic characteristics of human atria during chronic atrial fibrillation.

METHODS

The study was performed in 24 patients who underwent low energy intracardiac atrial cardioversion for chronic atrial fibrillation before the procedure itself. No patients have been assuming antiarrhythmic drugs for a period of at least 5 half-lives of the drug. In 10 patients the possibility of local capture in several atrial sites (7 tested) by means of high-rate atrial pacing was evaluated. A Franz catheter for recording of monophasic action potential (MAP) and for atrial stimulation was positioned in the right atrium at a distance of 1 cm from a quadripolar catheter which was also positioned for the recording of the bipolar electrogram by the distal and proximal pairs and of the unipolar electrogram by the distal electrode. A decapolar catheter for shock delivery was positioned in the coronary sinus as well. In the remaining 14 patients an additional quadripolar catheter for His recording was positioned but atrial stimulation was not performed. Furthermore, recordings of the bipolar and unipolar electrograms were obtained in several sites and the correlation between MAP and bipolar electrogram morphology was evaluated. The existence of a difference in fibrillation cycle-length in different sites suggestive of a dispersion of refractory periods was also screened. Wells' and Waldo's classification was used for bipolar electrograms whereas MAP was classified into type 1 (regular), type 2 (partially irregular), and type 3 (totally irregular).

RESULTS

In 10 patients submitted to atrial stimulation, local capture was obtained in 37 out of 43 stimulation sites (86%). Local capture was more frequently obtained in the lateral wall than in other sites (p < 0.05). The capture was obtained only in type 1 and type 2 atrial fibrillation. In the remaining 14 patients a perfect correlation (100%) between type 1 and 3 atrial fibrillation and type 1 and 3 MAP respectively was observed. In type 2 atrial fibrillation the correspondence was lower (67%). Fibrillation cycle-length contemporary recorded in the 6 different atrial sites were significantly different in 8 patients out of 12 (67%) in whom a stable recording could be obtained in basal conditions.

CONCLUSIONS

1) In chronic atrial fibrillation an excitable gap allowing local capture is present in the majority of patients and in most atrial sites, at least in the right atrium. 2) The morphology of bipolar and MAP recordings are fairly correlated and they reflect the complexity and the degree of synchronization of the arrhythmia. 3) A dispersion of refractoriness seems to contribute to the maintainance of the arrhythmia.

Indications for dual-chamber (DDD) pacing in implantable cardioverter-defibrillator patients

New technologic development of implantable cardioverter-defibrillators (ICDs) keeps up with the exponential increase of their use for primary and secondary prevention of sudden cardiac death. The first-generation ICD with limited shock capability alone could be considered adequate in most cardiac arrest victims, but it was not suitable for sudden death prevention in all high-risk patients with cardiac disease. The second-generation ICD was comprised of hybrid pacemaker-defibrillator systems that provided on-demand ventricular antibradycardia pacing. The third-generation devices include additional functions, such as antitachycardia pacing for ventricular tachycardia (VT) reversion and low-energy ventricular cardioversion, in addition to ventricular defibrillation and single-chamber ventricular demand pacing. In the near future, advanced dual-chamber atrioventricular (AV) pacing and defibrillating systems will also be available. The dual chamber ICD will allow atrial inhibited/dual-chamber (AAI/DDD) rate-responsive pacing, simultaneous atrial and ventricular sensing to optimize the arrhythmia identification, and ICD shock delivery in the proper arrhythmia-related chamber. Clinical benefits of these devices compared with their cost and complexity will require careful evaluation.